Newswise — Bethesda, MD (October 31, 2017)—Leading experts in the field of sickle cell disease (SCD) research will convene in Washington, D.C., for the Physiological and Pathophysiological Consequences of Sickle Cell Disease conference (November 6–8). The conference, organized by the American Physiological Society (APS), will explore SCD—the world’s most prevalent single-gene mutation disease—and new research on preventing and reversing its deadly consequences.
SCD affects millions of people around the world and more than 100,000 people in the U.S. In recent years, the prognosis of people with SCD has improved, but the only way to cure SCD is through a risky bone marrow transplant. “Currently, there is only one FDA-approved treatment for the disease,” said conference chair Dexter L. Lee, PhD, of Howard University in Washington, D.C. “Researchers across the country and around the globe are making progress in our understanding of the disease and the discovery of new therapies to serve the SCD community.” The goal of the conference is to convene an internationally recognized, interdisciplinary group of investigators to present and discuss current basic and clinical research findings in SCD and to develop new ideas and directions for future research in SCD.
Much of the science presented at the meeting will focus on translational research and new potential therapies, including causes of and treatment for pain, clotting and inflammation, and cell and gene therapy. The abstract-driven program will highlight both established researchers and trainees and early-career investigators giving oral and poster presentations of their work.
Monday, November 6, 2017
Opening Remarks: Harvey Luksenburg, National Institutes of Health; National, Heart, Lung and Blood Institute
Tuesday, November 7, 2017
Plenary Lecture Speaker: Wayne A. I. Frederick, Howard University, Washington, D.C.
Symposia I: Neural Circuits and Neurovascular Physiology Chair: Thomas D. Coates, University of Southern California
Targeting Pain at its Source in Sickle Cell Disease Speaker: Kalpna Gupta, University of Minnesota
Symposia II: SCD Gene Therapy, Gene Editing, and Pharmacological Treatment Chair: David Williams, Harvard Stem Cell Institute, Cambridge, Mass.
Gene Therapy for Hemoglobinopathies: The Challenge to Find a Cure Speaker: Giuliana Ferrari, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy
Discovery of Pharmacologic Fetal Hemoglobin Inducing Agents for Sickle Cell Disease Speaker: Betty Pace, Augusta University, Georgia
Symposia III: Cell Therapy Chair: Betty Pace, Augusta University, Georgia
Control of HbF Silencing: Implications for Genetic and Pharmacologic Induction of HbF for Therapy Speaker: Stuart Orkin, Harvard University, Cambridge, Mass.
CRISPR/Cas9 Enhanced Sickle Gene Correction in Human and Mouse Hematopoietic Stem Cells Speaker: Tim Townes, University of Alabama at Birmingham
Symposia IV: Small Molecules to Treat SCD Chair: James Douglas Engel, University of Michigan
KEAP1-NRF2 Antioxidant Response System and Sickle Cell Anemia Speaker: Masayuki Yamamoto, Tohoku University, Japan
Oral Tetrahydrouridine and Decitabine for Non-cytotoxic Epigenetic Modification of Sickle Cell Disease: A Randomized Phase 1/2 Study Speaker: Yogen Saunthurarajah, Cleveland Clinic
RN-1, an LSD-1 Inhibitor, Induces HbF in the Baboon (P. anubis) and Reduces Mitochondria-containing RBC in a SCD Mouse Model Speaker: Angela Rivers, University of Illinois, Chicago
Wednesday, November 8, 2017
Symposia V: Renal and Vascular Physiology Chair: Jennifer Pollock, University of Alabama at Birmingham
Sickle Cell Disease: When Endothelin Becomes a Nephrotoxic and Proinflammatory Cytokine Speaker: Pierre-Louis Tharaux, INSERM U970, Paris, France
Symposia VI: Lung Physiology and Pathophysiology Chair: Steffen Meiler, Augusta University, Georgia
TBD Speaker: Solomon Ofori-Acquah, University of Pittsburgh
Symposia VII: Red Cell Physiology Chair: Sergei Nekhai, Howard University, Washington, D.C.
Developmental Regulation of Erythroid Self-renewal Speaker: James Palis, University of Rochester Medical Center
Pathobiology of Sickle Red Cells: Implications for Pathophysiology of Sickle Cell Disease Speaker: Mohandas Narla, New York Blood Center
Symposia VIII: Coagulation and Thrombosis Chair: Felicity N. Gavins, Louisiana State University Health Sciences Center, and Rafal Pawlinski, University of North Carolina
De-clotting Sickle Cell Disease Speaker: Rafal Pawlinski, University of North Carolina
Promoting the Resolution of Inflammation in Sickle Cell Disease Speaker: Felicity N. Gavins, Louisiana State University Health Sciences Center
NOTE TO JOURNALISTS: The Physiological and Pathophysiological Consequences of Sickle Cell Disease conference will be held in Washington, D.C., November 6–8. Read the full program. To schedule an interview with the conference organizers or presenters, contact the APS Communications Office or call 301-634-7209. Find more research highlights in the APS Press Room.
Physiology is the study of how molecules, cells, tissues and organs function in health and disease. Established in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field. The Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.
MEDIA CONTACTRegister for reporter access to contact details
Physiological and Pathophysiological Consequences of Sickle Cell Disease conference